International Clinical Trials Registry Platform, Research Policy & Cooperation Department, World Health Organization, Geneva, Switzerland.
J Evid Based Med. 2009 Feb;2(1):1-7. doi: 10.1111/j.1756-5391.2009.01014.x.
In the 4 years between the Ministerial Forums on research and health held in Mexico in 2004 and Mali in 2008, the landscape of clinical trial registration changed significantly. When the ICMJE announced that they would no longer consider publishing the findings of clinical trials unless the research had been prospectively registered, they were key to shifting the way the clinical trials community thinks about research transparency. The argument in favour of greater transparency had been building for more than 20 years. By 2004 there was consistent and convincing evidence of the existence of publication bias and the damage this does to people's ability to make well informed decisions about health care. There is now increasing acceptance that the registration of clinical trials in a publicly accessible registry is a scientific, ethical and moral responsibility. In 2004, less than 3000 clinical trials were registered on databases meeting ICMJE criteria. There are now more than 19000 and, in some countries, prospective registration in a publicly accessible registry is now a legal requirement. Further, since October 2008, prospective registration is required if researchers wish to comply with the Declaration of Helsinki. However, despite these advances and incentives, trial registration in many countries remains far from comprehensive and stronger enforcement mechanisms may be needed in those countries.
在 2004 年于墨西哥和 2008 年于马里举行的两届部长级医学研究与卫生论坛之间的四年间,临床试验注册的格局发生了重大变化。当 ICMJE 宣布,除非研究已进行前瞻性注册,否则他们将不再考虑发表临床试验结果时,他们在改变临床试验界对研究透明度的看法方面发挥了关键作用。人们对提高透明度的呼吁已经持续了二十多年。到 2004 年,已经有了一致且令人信服的证据表明存在发表偏倚,而这会损害人们在医疗保健方面做出明智决策的能力。现在越来越多的人认为,在公众可访问的注册处注册临床试验是一种科学、伦理和道德责任。2004 年,符合 ICMJE 标准的数据库中仅注册了不到 3000 项临床试验。现在已经有超过 19000 项,并且在一些国家,在公众可访问的注册处进行前瞻性注册现在是一项法律要求。此外,自 2008 年 10 月以来,如果研究人员希望遵守《赫尔辛基宣言》,则需要进行前瞻性注册。然而,尽管取得了这些进展和激励措施,但许多国家的试验注册仍然远远不够全面,可能需要在这些国家实施更强有力的执行机制。